Leap reports Phase I data from DKN-01 plus Keytruda arm in esophageal cancer

Leap Therapeutics Inc. (NASDAQ:LPTX) reported data from seven evaluable patients with advanced esophagogastric cancer in the Phase I P102 trial showing that DKN-01 on days one and 15 of each 21-day cycle plus PD-1 inhibitor Keytruda pembrolizumab led to one partial response, plus five cases of stable disease. The partial response occurred in a patient who was naïve to anti-PD-1/PD-L1 therapy. Data were presented at the American Association for Cancer Research meeting in Chicago.

Leap has previously reported data from the monotherapy and the DKN-01 plus paclitaxel arms of the open-label, U.S. trial (see BioCentury, April 13)...